TABLE 5

Change in asthma profile from V2 (8 weeks) to V4 (36 weeks)

Unadjusted FeNO groupAdjusted FeNO groupAdjusted p-value
Asthma-related QoL
 ACQ#−0.2 (−0.7–0.3)−0.1 (−0.6–0.3)0.5
 Mini AQLQ#0.2 (−0.3–0.6)0.1 (−0.3–0.6)0.6
Spirometry
 RDR %·mg−1#,¶0.16 (−0.14–0.46)−0.02 (−0.05–0.02)0.3
 Mean FEV1 L0.08 (−0.01–0.17)0.07 (−0.02–0.16)0.1
 Mean FEV1 %2.5 (−0.3–5.2)2.3 (−0.5–5.0)0.1
 Mean FVC L#−0.10 (−0.22–0.03)−0.10 (−0.23–0.03)0.1
 Mean FEV1/FVC %#0.03 (−0.00–0.05)0.02 (−0.00–0.05)0.1
FeNO ppb#−17 (−36–2)−13 (−20– −5)0.001
Present treatment
 ICS dose µg#−25 (−224–174)5 (−194–204)1.0
 LABA dose µg#29 (−105–162)42 (−121–205)0.5
Inflammatory features
 Leukocyte ×109·L−1#−2.8 (−9.4–3.8)−3.1 (−9.8–3.6)0.4
 Eosinophil ×109·L−1#−0.06 (−0.21–0.09)0 (−0.10–0.11)0.9
 Neutrophil ×109·L−1#−0.2 (−1.2–0.9)−0.2 (−1.1–0.7)0.6
 CRP mg·L−1#−0.7 (−2.5–1.1)−0.7 (−2.2–0.9)0.4
 IgE kU·L−134 (−94–161)12 (−66–91)0.8
 IL-6 pg·mg−1−0.4 (−1.4–0.5)−0.2 (−0.7–0.3)0.4
 IL-8 pg·mg−171.2 (−155.8–298.2)62.4 (−143.9–268.7)0.6
Sputum inflammation
 Eosinophils %#−9.14 (−18.50–0.21)−7.91 (−16.83–1.01)0.1
 Neutrophils %2.1 (−17.3–21.5)2.2 (−16.4–20.7)0.8
 Macrophages %2.1 (−12.9–17.2)1.2 (−12.3–14.7)0.9
 Columnar epithelia %#4.9 (−7.9–17.7)4.8 (−8.1–17.6)0.5

Data are presented as mean differences (95% CI) based on linear regression analyses, unless otherwise stated. Changes in the Asthma Control Questionnaire (ACQ) group were used as reference. Crude and adjusted analyses were performed for the baseline level of the outcome. FeNO: exhaled nitric oxide fraction; QoL: quality of life; AQLQ: Asthma Quality of Life Questionnaire; RDR: response dose ratio; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroids; LABA: long-acting β2-agonist; CRP: C-reactive protein; Ig: immunoglobulin; IL: interleukin. #: in cases where the model assumptions were violated the effect estimates were checked with robust linear regression; : analysis of 26 patients in the FeNO group and 28 patients in the ACQ group.